ReviewCurrent cardiology reports2021
Vericiguat for Heart Failure with Reduced Ejection Fraction.
Review in Current cardiology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods.Frontiers in pharmacology · 2025Pooled it
- Efficacy and safety of vericiguat in heart failure: a meta-analysis.The Journal of international medical research · 2023Pooled it
- Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.Basic & clinical pharmacology & toxicology · 2022Pooled it
- The Influence of Basic Therapy and New Drugs on NO-Dependent Mechanisms of Cardiac Destruction in Chronic Heart Failure.Biomedicines · 2026Review
- Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry.European journal of heart failure · 2025Observational
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- Endothelial Dysfunction and Liver Cirrhosis: Unraveling of a Complex Relationship.International journal of molecular sciences · 2024Review
- Management of patients with heart failure and chronic kidney disease.Heart failure reviews · 2024Review
- Heart Failure With Improved Ejection Fraction: Prevalence, Predictors, and Guideline-Directed Medical Therapy.Cureus · 2024Review
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial.Frontiers in pharmacology · 2024Article
- Sudden cardiac death prevention in the era of novel heart failure medications.American heart journal plus : cardiology research and practice · 2023Review
- Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets.Frontiers in cardiovascular medicine · 2023Review
- Heart failure: an update from the last years and a look at the near future.ESC heart failure · 2022Review
- Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications.Biomedicines · 2022Review
- Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives.Pharmaceutics · 2022Review
- Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease.Pharmaceutics · 2022Review
- Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care.ESC heart failure · 2022Review
- Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis.Journal of clinical medicine · 2022Article
- Cost effectiveness analyses of pharmacological treatments in heart failure.Frontiers in pharmacology · 2022Review
- Vericiguat: A New Hope for Heart Failure Patients.Cardiovascular therapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway plays an important role in the regulation of cardiovascular function, and it is disrupted in heart failure (HF), resulting in decreased protection against myocardial injury. Impaired NO-sGC-cGMP signaling in HF is secondary to reduced NO bioavailability and altered redox state of sGC, which becomes less responsive to NO. The sGC activator cinaciguat increases cGMP levels by direct NO-independent activation of sGC and may be particularly effective in conditions of increased oxidative stress and endothelial dysfunction, and therefore reduced NO levels, at the expense of a greater risk of hypotension. Conversely, sGC stimulators (riociguat and vericiguat) enhance sGC sensitivity to endogenous NO, thus exerting a more physiological action. RECENT
findingsClinical trials have suggested the benefit of vericiguat in patients with high-risk HF; in particular, a lower incidence of death from cardiovascular causes or HF hospitalization. Adding vericiguat may be considered in individual patients with HF, and reduced left ventricular ejection fraction (HFrEF) particularly those at higher risk of HF hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.